National Research Institute

Huntington Park, California 90255

0 studies enrolling now · 24 studies all time

What they study most

Diabetes Mellitus, Type 2, Fibrosis, Liver, Hypercholesteremia, Mixed Dyslipidaemia, NAFLD, NASH - Nonalcoholic Steatohepatitis, Non Alcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Steatohepatitis With Liver Fibrosis, Painful Diabetic Peripheral Neuropathy

Studies at this site

• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 — Completed
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus — Completed
• A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis — Status unconfirmed
• Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy — Completed
• A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. — Completed
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis — Status unconfirmed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) — Stopped early
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone — Completed
• Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) — Completed
• A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus — Completed
• A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
• A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia — Completed
• A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins — Completed
• A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
• Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin — Stopped early
• Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM — Completed
• Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM — Completed